• culpritus [any]@hexbear.net
    link
    fedilink
    English
    arrow-up
    16
    ·
    13 days ago

    Seems to be only specific to ibogaine, which is good but still quite restrictive to many other valuable therapy research potentials.

    • dead [he/him]@hexbear.netOP
      link
      fedilink
      English
      arrow-up
      21
      ·
      13 days ago

      (b) The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a), including any necessary Schedule I handling authorizations for treating physicians and researchers, consistent with 21 U.S.C. 823, and any applicable waiver authority under the Controlled Substances Act.

      The executive order linked below. It says “establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds”. It gives ibogaine as an example, not as a limit.

      I think the catch is that they will limit the “eligible patients” to be mostly US Military Veterans.

      https://archive.is/DkYl1